HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin.

AbstractOBJECTIVE:
Voglibose is a new and potent inhibitor of alpha-glucosidases and is used for the treatment of diabetes mellitus. Since voglibose increases gastrointestinal motility and could thus affect absorption of concomitantly administered drugs, it was investigated whether or not voglibose modifies the pharmacodynamics and pharmacokinetics of warfarin, an oral anticoagulant frequently used in cardiovascular disorders likely to arise in diabetic patients.
METHODS:
Twelve healthy male subjects were given individually adjusted doses of warfarin to reduce prothrombin time (Quick's method) to a value of about 30-40% of the normal range within the first 8 days. Then, the individuals maintenance dose, given in the morning, was maintained until day 15. On study days 11-15, voglibose was co-administered per os in a dose of 5 mg t.i.d. The prothrombin time was determined on days 10 and 11 (reference) and on days 15 and 16 (test), and the steady-state pharmacokinetic characteristics of the warfarin enantiomers were determined on days 10 (reference) and 15 (test). The ratios test/reference were evaluated according to bioequivalence criteria.
RESULTS:
The equivalence ratio (test reference) for the pharmacodynamic parameter prothrombin time was 0.97 and for the pharmacokinetic characteristics AUC0-24 h.t.ss: S-(-)-warfarin, 1.05; R-(+)-warfarin, 1.01; and Cmax.ss: S-(-)-warfarin, 1.08; R-(+)-warfarin, 1.04. All parameters were within the predetermined accepted range of 0.7-1.43 (pharmacodynamics) or 0.8-1.25 (pharmacokinetics), thus fulfilling equivalence criteria.
CONCLUSIONS:
Voglibose modified neither the pharmacodynamics nor the pharmacokinetics of warfarin under steady-state conditions. Concomitant treatment was well tolerated and has been proven to be safe for further clinical use.
AuthorsH Fuder, P Kleist, M Birkel, A Ehrlich, S Emeklibas, W Maslak, E Stridde, N Wetzelsberger, G Wieckhorst, P W Lücker
JournalEuropean journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 53 Issue 2 Pg. 153-7 ( 1997) ISSN: 0031-6970 [Print] Germany
PMID9403289 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Anticoagulants
  • Enzyme Inhibitors
  • Glycoside Hydrolase Inhibitors
  • Inositol
  • Warfarin
  • voglibose
Topics
  • Adult
  • Anticoagulants (pharmacokinetics, pharmacology)
  • Area Under Curve
  • Chromatography, High Pressure Liquid
  • Drug Interactions
  • Enzyme Inhibitors (pharmacology)
  • Female
  • Glycoside Hydrolase Inhibitors
  • Humans
  • Inositol (analogs & derivatives, pharmacology)
  • Male
  • Prothrombin Time
  • Reference Values
  • Warfarin (pharmacokinetics, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: